tbuckley/cabot-search huggingface dataset:
Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer
Authors: Sue Jin Moon, Byong Chang Jeong, Hwa Jin Kim, Joung Eun Lim, Hye-Jeong Kim, Ghee Young Kwon, Joshua A. Jackman, Jeong Hoon Kim
Journal: Theranostics (2020)

Rationale: Aberrant androgen receptor (AR) signaling via full-length AR (AR-FL) and constitutively active AR variant 7 (AR-V7) plays a key role in the development of castration-resistant prostate cancer (CRPC) and resistance to hormone therapies.Simultaneous targeting of AR-FL and AR-V7 may be a promising strategy to overcome resistance to hormone therapy.This study aimed to identify novel drug candidates co-targeting AR-FL and AR-V7 activities and elucidate their molecular mechanism of anti-CRPC activities.Methods: Using a CRPC cell-based reporter assay system, we screened a small library of antimalarial agents to explore the possibility of repositioning them for CRPC treatment and identified bruceantin (BCT) as a potent anti-CRPC drug candidate.A series of cell-based, molecular, biochemical, and in vivo approaches were performed to evaluate the therapeutic potential and molecular mechanism of BCT in CRPC.These approaches include reporter gene assays, cell proliferation, RNA-seq, qRT-PCR, mouse xenografts, co-immunoprecipitation, GST pull-down, immobilized BCT pull-down, molecular modeling, and bioinformatic analyses.Results: We identified BCT as a highly potent inhibitor co-targeting AR-FL and AR-V7 activity.BCT inhibits the transcriptional activity of AR-FL/AR-V7 and downregulates their target genes in CRPC cells.In addition, BCT efficiently suppresses tumor growth and metastasis of CRPC cells.Mechanistically, BCT disrupts the interaction of HSP90 with AR-FL/AR-V7 by directly binding to HSP90 and inhibits HSP90 chaperone function, leading to degradation of AR-FL/AR-V7 through the ubiquitin-proteasome system.Clinically, HSP90 expression is upregulated and correlated with AR/AR-V7 levels in CRPC.Conclusion: Our findings suggest that BCT could serve as a promising therapeutic candidate against CRPC and highlight the potential benefit of targeting AR-FL/AR-V7-HSP90 axis to overcome resistance caused by aberrant AR-FL/AR-V7 signaling.
Generalized Intestinal Polyposis and Melanin Spots of the Oral Mucosa, Lips and Digits
Authors: Harold Jeghers, Victor A. McKusick, Kermit H. Katz
Journal: New England Journal of Medicine (1949)

DiscussionTable 2 and 3 summarize data concerning our 10 proved cases of intestinal polyposis that manifested a distinctive variety of melanin spots of the oral mucosa, lips and digits.The ages of these 10 patients ranged from nine to thirty-nine at the time of death or first study by us. In each case, however, symptomatology referable to the intestinal polyposis had been present before, usually beginning in the teens. The patients of Peutz7,10 and the one of Touraine and Couder17,18 were in an age range similar to that in our series. Apparently, the type of intestinal polyposis present in this condition becomes . . .
Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML)
Authors: Anthony S. Stein, Monzr M. Al Malki, Dongyun Yang, Joycelynne Palmer, Ni-Chun Tsai, Ibrahim Aldoss, Haris Ali, Ahmed Aribi, Andrew S. Artz, Len Farol, Susanta Hui, Chatchada Karanes, Samer Khaled, An Liu, Guido Marcucci, Ryotaro Nakamura, Vinod A. Pullarkat, Eric Radany, Joseph Rosenthal, Amandeep Salhotra, James F Sanchez, Ricardo Spielberger, David S Snyder, Stephen J. Forman, Jeffrey Wong
Journal: Blood (2020)
Assessing Early Mortality in Intensively-Treated Acute Myeloid Leukemia in a Developing Country: Genetic, Laboratory Findings, and Comorbidities Add Prognostic Information
Authors: Fernanda Rodrigues Mendes, Wellington F Silva, Raphael Bandeira Melo, Douglas R. A. Silveira, Elvira Velloso, Vanderson Rocha, Eduardo M Rego
Journal: Blood (2020)
Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study
Authors: Evangelos Terpos, Efstathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, Evangelos Eleutherakis-Papaiakovou, Evgenia Verrou, Maria Gavriatopoulou, Alexandros Leonidakis, Ioannis Ntanasis-Stathopoulos, Sosana Delimpasi, Marie-Christine Kyrtsonis, Maria Papaioannou, Argiris Symeonidis, Meletios A Dimopoulos
Journal: Blood (2020)
A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-Life Provides Dual Conditioning and Anti-Leukemic Activity and Extends Survival Compared to Standard of Care in Multiple Preclinical Models of Acute Myeloid Leukemia (AML)
Authors: Leanne Lanieri, Tahirih L Lamothe, Oliver Miske, Sean M McDonough, Ganapathy N Sarma, Prashant Bhattarai, Kellie Latimer, Junia Dushime, Nidhi Jain, Rahul Palchaudhuri, Ryan Knihtila, Bradley R Pearse, Jennifer L Proctor, Anthony E Boitano, Michael P Cooke, John C. Davis
Journal: Blood (2020)
Same-day repeatability of fractional exhaled nitric oxide in severe asthma
Authors: Ran Wang, Fahad Alahmadi, Robert Niven, Stephen J. Fowler
Journal: European Respiratory Journal (2021)

<b>Fractional exhaled nitric oxide (<i>F</i><sub>ENO</sub>) demonstrates marked same-day variation in patients with severe asthma, which may impact on clinical decisions. The same-day variability must be carefully considered when interpreting <i>F</i><sub>ENO</sub> as a single-breath test.</b>https://bit.ly/38M1eJV
Acute Promyelocytic Leukemia (APL): Seasonal Behavior in Colombia for the Period 2009-2019
Authors: Humberto Martínez Cordero, Juan Ospina Idarraga, Xiomara Castañeda Contreras, Alejandro Rico Mendoza, Henry Idrobo, Lina Martinez Correa, Jenifer Buitrago, Alexandra Porras Ramírez
Journal: Blood (2020)
Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)
Authors: Shukaib Arslan, Jianying Zhang, Prajwal Dhakal, Jenna A. Moran, Nuthana Naidoo, Jennifer Lombardi Story, Vinod A. Pullarkat, Anthony S. Stein, Guido Marcucci, George Yaghmour, Vijaya R. Bhatt, Amir T. Fathi, Ibrahim Aldoss
Journal: Blood (2020)
Abstract IA05: Deciphering the immune microenvironment with spatial histology
Authors: Yinyin Yuan
Journal: Cancer Research (2020)

Abstract Tumours are complex, evolving ecosystems with dynamic crosstalk among cancer and normal cells. Measuring spatial heterogeneity in the tumour microenvironment is critical for understanding the spatial context in which cancer develops and evolves. I will discuss quantitative spatial histology measures of immune response as a result of combining automated histology image analysis and spatial statistics. Geospatial variation in the immune microenvironment can have profound clinical implications, even in cancers with low immunogenicity, such as estrogen-receptor positive breast cancer. I will also share our recent progress on studying the geospatial complexity of tumour microenvironment in the TRACERx study of lung cancer evolution. Citation Format: Yinyin Yuan. Deciphering the immune microenvironment with spatial histology [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr IA05.
Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT)
Authors: Jack W. Hsu, Nosha Farhadfar, Hemant S. Murthy, Brent Logan, Stephanie Bo-Subait, Noelle V. Frey, Steven C. Goldstein, Mary M. Horowitz, Hillard M Lazarus, Joshua Schwanke, Nirali N. Shah, Stephen R. Spellman, Galen E. Switzer, Steven M Devine, Bronwen E. Shaw, John R. Wingard
Journal: Blood (2020)
Impact of Cutaneous Involvement on the Clinical Outcome of Adult T-Cell Leukemia/Lymphoma: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL)
Authors: Luis E Malpica Castillo, Denisse A. Castro, Camila Peña, Henry Idrobo, Daniel J Enriquez, Lorena Fiad, Maria Prates, Victoria Otero, Mirna Churin, Milagros Altamirano, Kelly Meza, Celia Moises, Roberto Oviedo-Pecho, Antonio Paredes, Gadwyn Sanchez, Laura Aguirre-Martinez, Bryan Valcarcel, Cristaldo Nancy, Juan L. Maradei, Luciana Guanchiale, Pablo Soto, Jose Luis Viñuela, Maria Elena Cabrera, Ursula Aviles-Perez, Gustavo Sandival-Ampuero, Sally Rose Paredes, Eloisa Riva, Marcos Di Stefano, Andrea Noboa, Juan Antonio Choque, Myrna Candelaria, Alana Von Glasenapp, Fabiola Valvert, Marialejandra Torres Viera, Guilherme Fleury Perini, Eduardo Sotomayor, Jorge J. Castillo, Juan Carlos Ramos, Luis Villela Villela, Brady Beltran
Journal: Blood (2020)
PTU-049 Patients with ‘missed’ interval colorectal cancers on the national faecal occult blood testing programme may not be truly asymptomatic – results from a multicentre study
Authors: AT George, S Aggarwal, S Dharmavaram, A Menon, M Dube, M Vogler, A Field
Journal: Gut (2017)

Introduction  To identify symptomatology of interval cancers(IC-cancers diagnosed within 2 years of a negative Faecal Occult Blood Testing(FOBT)).  Method  National Bowel Cancer Audit Programme data from three centres,for all colorectal cancers(CRC)in the screening age group(60–74 years)over a 2 year period(August 2011–2013)were linked for their Faecal Occult Blood Testing(FOBT)screening status(BCSP database/Eastern Hub).Detailed symptomatology of IC were analysed.Tumours at and beyond splenic flexure were considered left-sided.  Results  The study covered 2 million population( 2 00 000 screening eligible). 521 CRC were diagnosed(0.11%). 231 CRC(44%)were in patients who had declined screening, 162 CRC(31%)were screen-detected and 128 CRC(25%)were IC.  Of these 128 patients(M: F; 84:44),median age 67 years(SD: 3.8)the commonest presenting symptoms was change in bowel habits in 50 (39%).Others included bleeding per-rectum( 44 (34%)patients,abdominal pain 38 (30%),anaemia 36 (28%),loss of weight 14 (11%),bowel obstruction 13 (10%),bowel perforation in 3 (2%) patients. Only two patients were truly asymptomatic-CRC being identified in oneduring gynaecological surgery and during trauma laparotomy in the other.  In the anaemic patients(36 (28%)) the blood picture showed Hb(mean;10.3 gm);MCV( 82.4);MCH(26.3).61% of anaemic patients had CRC in the right colon with an equal percentage being of Duke’s stage C/D.  The time from negative FOB test to CRC diagnosis was 15 months (0.5–24 months).  Conclusion  Our findings highlight majority of IC patients were symptomatic with ‘red flag symptoms’. We raise the possibility of a natural bias in patients volunteering for the FOB test in that they may have bowel symptoms not yet discussed with their general practitioner. We highlight the need for improved awareness to reduce delays in symptomatic patients seeking medical advice against a background of a negative FOBT.  Disclosure of Interest  None Declared
Abstract 415: Asporin Contributes to Reactive Interstitial Cardiac Fibrosis by Regulating Cardiac Fibroblast Activation
Authors: Lejla Medzikovic, Laila Aryan, Gregoire Ruffenach, Mansoureh Eghbali
Journal: Circulation Research (2020)

Cardiac fibrosis critically contributes to heart failure progression. Depending on the pathological insult, cardiac fibrosis either replaces necrotic cardiomyocytes or is reactive to cardiac fibroblast (CF) activation. The extracellular matrix (ECM) consists of various proteins and the role of fibrillar collagen has been well studied. However, the role of non-fibrillar ECM proteins in cardiac fibrosis is less clear. To explore the role of ECM in reactive cardiac fibrosis, we performed bioinformatic analysis on online available microarray GEO datasets from hearts of human hypertrophic cardiomyopathy patients and two mouse models of transverse aortic constriction and Angiotensin II (AngII) infusion. We found that 27 differentially expressed genes were common between the three datasets. Among these genes was the small leucine-rich proteoglycan Asporin (ASPN). ASPN was previously shown to be upregulated in the ECM of replacement fibrosis in porcine ischemia/reperfusion injury. However, not much is known about the role of ASPN in reactive interstitial fibrosis. We show that cardiac ASPN expression is enhanced in mice after short- and long-term AngII infusion compared to saline infusion. In resident CF isolated from adult mice, ASPN expression is upregulated by both AngII and TGF-β stimulation. Here, ASPN expression correlates with a gene signature of activated CFs including periostin ( postn ), α-smooth muscle actin ( acta2 ) and collagens I and III ( col1a1, col3a1 ), and with functional characteristics of activated CFs including proliferation, migration and collagen production. Modulating ASPN via siRNA in mouse resident CFs inhibits postn, acta2, col1a1 and col3a1 expression and total collagen production, indicating repressed CF activation upon ASPN knockdown. Taken together, ASPN may be an attractive novel target against reactive interstitial fibrosis.
Classification of facial and truncal segmental vitiligo and its clinical courses including recurrence rate and patterns: a retrospective review of 956 patients
Authors: J. Oh, R.W. Lee, H.R. Lee, S.B. Lee, H.J. Ju, J. Park, H.R. Park, J.H. Park, S‐K. Hann, A. Almurayshid, J. Shin, H.Y. Kang, J.M. Bae, S.H. Oh
Journal: British Journal of Dermatology (2020)

Classification of facial and truncal segmental vitiligo and its clinical courses including recurrence rate and patterns: a retrospective review of 956 patients
The<i>in Vitro</i>procoagulant Effects of Standard and Extended Half-Life Recombinant Factor IX Concentrates in Patients on Prophylaxis with Emicizumab
Authors: Elena G Arias-Salgado, Ihosvany Fernandez-Bello, Elena Monzón Manzano, Paula Acuña, Sara García Barcenilla, María Teresa Alvarez Román, Mónica Martín, María Isabel Rivas Pollmar, Tamara Cebanu, Elena González Zorrilla, Miguel A Canales, Nora V. Butta, Victor Jimenez-Yuste
Journal: Blood (2020)
Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients
Authors: Angelica D'Aiello, Sumaira Zareef, Kith Pradhan, Amanda Lombardo, Fariha Khatun, Jennat Mustafa, Alyssa De Castro, Felisha Joseph, Kailyn Gillick, Anjali Naik, Astha Thakkar, Lauren C Shapiro, Shafia Rahman, Zhu Cui, Jesus D Gonzalez Lugo, Fiona Mienko, Numa Tarnima Rahman, Robert Lopez, Heidi Chwan Ko, Amanda Podolski, Vikas Mehta, Sanjay Goel, Rafi Kabarriti, Joseph Sparano, Stuart Packer, David Lawrence Fernandes, Enrico Castelucci, Margarita Kushnir, Mark Chaitowitz, Luca Paoluzzi, Ulrich G. Steidl, Phaedon Zavras, Ioannis Mantzaris, Noah Kornblum, Aditi Shastri, Lizamarie Bachier-Rodriguez, Kira Gritsman, Henny H. Billett, Rachel Bartash, Yoram Puius, Margaret Mccort, Ira Braunschweig, Mendel Goldfinger, Amit Verma, R. Alejandro Sica
Journal: Blood (2020)
Rare Thyroid Cartilage Metastasis From Breast Cancer Visualized on 18F-NaF PET/CT
Authors: Sharjeel Usmani, Najeeb Ahmed, Muhammad Waqas Ilyas, Sarah Murad, Fareeda Al Kandari
Journal: Clinical Nuclear Medicine (2020)

Metastatic involvement of the thyroid cartilage is rare due to the absence of vessels within the cartilaginous tissue. We present the case of a 65-year-old woman recently diagnosed with breast cancer referred for skeletal staging with F-NaF PET/CT. She was found to have multiple osteoblastic metastases along with thyroid cartilage metastasis. Rare thyroid cartilage metastasis on F-NaF PET/CT may have prognostic significance in cancer patients.
Cost-effectiveness of Sexually Transmitted Infection Screening for Adolescents and Young Adults in the Pediatric Emergency Department
Authors: Mark H. Eckman, Jennifer L. Reed, Maria Trent, Monika K. Goyal
Journal: JAMA Pediatrics (2020)

Adolescents and young adults compose almost 50% of all diagnosed sexually transmitted infection (STI) cases annually in the US. Given that these individuals frequently access health care through the emergency department (ED), the ED could be a strategic venue for examining the identification and treatment of STIs.To examine the cost-effectiveness of screening strategies for Chlamydia trachomatis and Neisseria gonorrhoeae (chlamydia and gonorrhea) in adolescents and young adults who seek acute care at pediatric EDs.This economic evaluation is a component of an ongoing, larger multicenter clinical trial at the Pediatric Emergency Care Applied Research Network. A decision analytic model, created using literature-based estimates for the key parameters, was developed to simulate the events and outcomes associated with 3 strategies for screening and testing chlamydial and gonococcal infections in individuals aged 15 to 21 years who sought acute care at pediatric EDs. Data sources included published (from January 1, 1997, to December 31, 2019) English-language articles indexed in MEDLINE, bibliographies in relevant articles, insurance claims data in the MarketScan database, and reimbursement payments from the Centers for Medicare and Medicaid Services. Because the events and outcomes were simulated, a hypothetical population of 10 000 ED visits by adolescents and young adults was used.The 3 screening strategies were (1) no screening, (2) targeted screening, and (3) universally offered screening. Targeted screening involved the completion of a sexual health survey, which yielded an estimated STI risk (at risk, high risk, or low risk).Outcome metrics included cost (measured in 2019 US dollars) and the detection and successful treatment of STIs. The incremental cost-effectiveness ratio (ICER) of each strategy was calculated in a base case analysis. The ICER reflects the cost per case detected and successfully treated.A 3.6% prevalence of chlamydia and gonorrhea was applied to a hypothetical population of 10 000 ED visits by adolescents and young adults. Targeted screening resulted in the detection and successful treatment of 95 of 360 STI cases (26.4%) at a cost of $313 063, and universally offered screening identified and treated 112 of 360 STI cases (31.1%) at a cost of $515 503. The ICER for targeted screening vs no screening was $6444, and the ICER for universally offered screening vs targeted screening was $12 139.This economic evaluation found that targeted screening and universally offered screening compared with no screening appeared to be cost-effective strategies for identifying and treating chlamydial and gonococcal infections in adolescents and young adults who used the ED for acute care. Universally offered screening was associated with detecting and successfully treating a higher proportion of STIs in this population.
Abstract IA22: Single cell proteomics to capture human dysplasia and dysfunction
Authors: Sean Bendall
Journal: Cancer Research (2020)

Abstract Single cell analysis, starting with the earliest low parameter fluorescent cytometry and microscopy experiments, helped define the major cell subsets of human cellular systems as we understand them today. Now, a novel combination of elemental mass spectrometry with single cell analysis (mass cytometry – CyTOF, Science 2011) and imaging (multiplexed ionbeam imaging – MIBI, Nature Med. 2014, Cell 2018) offers routine examination of &amp;gt;50 parameters without fluorescent agents or interference from spectral overlap using heavy metal isotopes as reporters. With these platforms, we have reached new levels of organizational understanding in human pathobiology. Here, we will review the evolution of these technologies and present our latest efforts to create assays with these platforms in order to quantify multiple levels of regulation including metabolism, proteome dynamics, and chromatin content regulating the epigenome. Further to this, we will highlight recent efforts to leverage structural characteristics of leukemia dysplasias to facilitate automated identification and classification from multiplexed single cell datasets (Tsai &amp; Glass et al. Nature Med. 2020). Overall, these new approaches can reveal new layers of human cellular organization and structure that can be exploited to understand dysfunction in general and provide avenues for more automated and robust clinical classification. Citation Format: Sean Bendall. Single cell proteomics to capture human dysplasia and dysfunction [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr IA22.
Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
Authors: Dae-Won Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Seock-Ah Im, Tae-You Kim, Youngeun Lee, Haeryoung Kim, Kyung-Hun Lee
Journal: Clinical Cancer Research (2020)

Abstract Purpose: This study investigated the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with advanced hepatocellular carcinoma previously treated with sorafenib (NCT03389126). Patients and Methods: This is a single-arm, single center, phase II trial. Patients with Child-Pugh A score who had at least one measurable lesion were enrolled. Intravenous avelumab 10 mg/kg every 2 weeks was given until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) according to RECIST v1.1. Secondary endpoints included time to progression (TTP), overall survival (OS), disease control rate (DCR), and safety. Results: A total of 30 patients were enrolled. After a median follow-up of 13.9 months, 27 progression events and 20 death events occurred. There was no complete response, three (10.0%) partial responses, and 19 patients (63.3%) with stable disease. ORR was 10.0% and DCR was 73.3%. The median TTP and OS was 4.4 and 14.2 months, respectively. PD-L1 expression did not affect avelumab response. Prior duration of sorafenib treatment, when dichotomized by the median 2.7 months, was associated with treatment outcome. TTP (6.5 vs. 1.8 months, P = 0.007) and OS (19.0 vs. 7.8 months, P = 0.006) were superior in patients with longer sorafenib duration. There was tendency of higher ORR (20.0% vs. 0.0%, P = 0.22) in those with longer sorafenib duration. Avelumab was well tolerated with seven grade 3 adverse events and no grade 4 adverse events. Conclusions: Avelumab showed moderate efficacy and was well tolerated in advanced hepatocellular carcinoma previously treated with sorafenib.
Impact and Dynamics of <i>TP53</i> Mutated Clones in Shwachman Diamond Syndrome in a Series of 80 Patients
Authors: Jean-Alain Martignoles, Pierre Hirsch, Blandine Beaupain, Thomas Longval, Nawa Hachem, Mira El-Khoury, Sophie Kaltenbach, Jean Soulier, Thierry Leblanc, Pierre Simon Rohrlich, Eric Jeziorski, Isabelle Meyts, Dalila Adjaoud, Vincent Barlogis, Marlène Pasquet, Laetitia Largeaud, Flore Sicre de Fontbrune, Claire Fieschi, Virginie Gandemer, Nathalie Aladjidi, Fanny Fouyssac, Guy Leverger, Wadih Abou Chahla, Stephane Blanche, Despina Moushous, Aline Moignet Autrel, Yves Bertrand, Cecile Renard, Pascale Flandrin-Gresta, Jean Louis Stephan, Olivier Tournilhac, Liana Carausu, Frederic Millot, Marielaure Couec, Claude Preudhomme, Hélène Lapillonne, Vahid Asnafi, Patrick Revy, Christine Bellanne-Chantelot, Francois Delhommeau, Jean Donadieu
Journal: Blood (2020)
Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients
Authors: Srdan Verstovsek, Miklos Egyed, Ewa Lech-Marańda, Tomasz Sacha, Viviane Dubruille, Stephen T. Oh, Doroteya Todorieva-Todorova, Francesco Passamonti, Blanca Xicoy, Björn Andréasson, Daniel El Fassi, Claire Harrison, Donal P. McLornan, Mary Frances Frances McMullin, Christof Scheid, MArianne Tang Severinsen, Mark M Kowalski, Gregg Smith, Ruben Mesa
Journal: Blood (2020)